Related Experiment Video
Updated: Aug 7, 2025
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
14.9K
Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies
Ava Safaroghli-Azar1, Fatemeh Emadi1, Jimma Lenjisa1
1Drug Discovery and Development, University of South Australia, UniSA Clinical and Health Sciences, SA 5000, Australia.
Drug Discovery Today
|March 12, 2023
Summary
Kinase inhibitors are revolutionizing cancer treatment by enhancing immunotherapy. These drugs not only target cancer cells directly but also stimulate immune responses, marking a significant advance in cancer therapy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Immunotherapy is the fifth pillar of cancer treatment, revolutionizing therapeutic strategies.
- Kinase inhibitors have emerged as a key development in immunotherapy.
- These inhibitors offer dual action: direct tumor eradication and immune response modulation.
Purpose of the Study:
- To review the current applications of kinase inhibitors in cancer immunotherapy.
- To summarize the challenges and future directions of kinase inhibitors as a therapeutic approach.
- To explore the role of kinase inhibitors as single agents and in combination therapies.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of the mechanisms of action for kinase inhibitors in immunotherapy.
- Synthesis of data on efficacy and safety profiles.
Main Results:
- Kinase inhibitors demonstrate direct anti-tumor effects by targeting critical cell survival proteins.
- These agents can potentiate anti-tumor immune responses, enhancing immunotherapy efficacy.
- Combined modalities involving kinase inhibitors show promise in overcoming treatment resistance.
Conclusions:
- Kinase inhibitors represent a significant advancement in cancer immunotherapy.
- Further research is needed to optimize their use and overcome existing challenges.
- Their dual mechanism of action positions them as crucial agents in future cancer treatment paradigms.
Related Concept Videos
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
606
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
606
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.6K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K